Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio M Grimaldi

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Melanoma Management|September 8, 2018
Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trialAntonio M Grimaldi, Ester Simeone, Paolo A Ascierto
Methods in Molecular Biology (Clifton, N.J.)|November 22, 2013
Marker utility for combination therapyEster Simeone, Antonio M Grimaldi, Paolo A Ascierto
Melanoma Management|September 8, 2018
Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanomaEster Simeone, Antonio M Grimaldi, Paolo A Ascierto
Current Opinion in Oncology|January 15, 2014
The role of MEK inhibitors in the treatment of metastatic melanomaAntonio M Grimaldi, Ester Simeone, Paolo A Ascierto
Cancer Treatment and Research|October 12, 2013
Novel approaches in melanoma prevention and therapyAntonio M Grimaldi, Pamela B Cassidy, Sancy Leachmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2013
Clinical development of immunostimulatory monoclonal antibodies and opportunities for combinationIgnacio Melero, Antonio M Grimaldi, Jose L Perez-Gracia, et al.
Clinical Case Reports|January 25, 2021
New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapyAgostino Guida, Francesco Perri, Franco Ionna, et al.
Journal of Translational Medicine|May 30, 2012
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical usePaolo A Ascierto, Ester Simeone, Diana Giannarelli, et al.
Oncoimmunology|January 4, 2018
PD-L1 inhibitors in the pipeline: Promise and progressVito Vanella, Lucia Festino, Martina Strudel, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 7, 2017
Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of CareEster Simeone, Antonio M Grimaldi, Lucia Festino, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Melanoma Management|September 8, 2018
Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trialAntonio M Grimaldi, Ester Simeone, Paolo A Ascierto
Methods in Molecular Biology (Clifton, N.J.)|November 22, 2013
Marker utility for combination therapyEster Simeone, Antonio M Grimaldi, Paolo A Ascierto
Melanoma Management|September 8, 2018
Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanomaEster Simeone, Antonio M Grimaldi, Paolo A Ascierto
Current Opinion in Oncology|January 15, 2014
The role of MEK inhibitors in the treatment of metastatic melanomaAntonio M Grimaldi, Ester Simeone, Paolo A Ascierto
Cancer Treatment and Research|October 12, 2013
Novel approaches in melanoma prevention and therapyAntonio M Grimaldi, Pamela B Cassidy, Sancy Leachmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2013
Clinical development of immunostimulatory monoclonal antibodies and opportunities for combinationIgnacio Melero, Antonio M Grimaldi, Jose L Perez-Gracia, et al.
Clinical Case Reports|January 25, 2021
New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapyAgostino Guida, Francesco Perri, Franco Ionna, et al.
Journal of Translational Medicine|May 30, 2012
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical usePaolo A Ascierto, Ester Simeone, Diana Giannarelli, et al.
Oncoimmunology|January 4, 2018
PD-L1 inhibitors in the pipeline: Promise and progressVito Vanella, Lucia Festino, Martina Strudel, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 7, 2017
Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of CareEster Simeone, Antonio M Grimaldi, Lucia Festino, et al.
Pageof 4